Lancet oncol: Is the secondary cytoreductive surgery beneficial to platinum-sensitive recurrent ovarian cancer?

The benefits of secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer are still widely debated.

The purpose of this study was to evaluate the efficacy of secondary tumor reduction surgery plus chemotherapy versus chemotherapy alone in this patient population.

This is a multi-center, open-label, randomized controlled study conducted in many mainstream medical academic centers in China ( Fudan Zhongshan Hospital, Fudan Obstetrics and Gynecology Hospital, Chinese University of Science and Technology Cancer Hospital, Sun Yat-sen University Cancer Center, Southeast University Zhongda Hospital, etc.

From July 19, 2012 to June 3, 2019, a total of 357 patients were randomly assigned to the surgery group (182) or the no surgery group (175).

The median follow-up was 36.

Progression-free survival

The median progression-free survival of the surgery group and the non-surgery group were 17.

Subgroup analysis of progression-free survival

In the mid-term overall survival analysis, the median overall survival of the surgery group and the no-surgery group were 58.

Adverse reactions

In the safety analysis population, 9 out of 172 patients (5%) in the surgical group had a grade 3-4 surgical morbidity within 30 days, and none of the two groups died within 60 days of receiving the designated treatment.

For patients with platinum-sensitive recurrent ovarian cancer, compared with chemotherapy alone, secondary cytoreductive surgery followed by chemotherapy can significantly prolong the progression-free survival of patients .

Tingyan Shi, et al.